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SUMMARY 
Background: There is evidence linking the Metabolic 
Syndrome with an increased risk of developing cardio-
vascular disease, previously thought to be rare in Af-
rica but now a major public health concern.  
Objectives: To determine the frequency of occurrence 
of the Metabolic Syndrome among patients presenting 
with cardiovascular disease at the Korle Bu Teaching 
Hospital, Ghana.  
Methods: This was a case-control study of 100 con-
secutive cardiovascular disease patients and 100 age- 
and sex- matched controls who underwent an interview 
and physical examination. Anthropometric measure-
ments and fasting blood samples for plasma glucose 
and lipids were taken. The National Cholesterol Educa-
tion Programme: Adult Treatment Panel III criteria 
were used for the diagnosis of the Metabolic Syn-
drome. 
Results: The prevalence of Metabolic Syndrome 
among cases and controls was 54% and 18% respec-
tively, with the prevalence increasing with advancing 
age. Hypertension and central obesity were the two 
components with the highest frequency among indi-
viduals with Metabolic Syndrome. The Metabolic Syn-
drome was associated with the development of cardio-
vascular disease (OR = 5.35, 95% CI: 2.81 – 10.18, p= 
0.0001), with the odds ratio increasing with the number 
of components present. 
Conclusion: The Metabolic Syndrome is prevalent 
among cardiovascular disease patients attending the 
Korle Bu Teaching Hospital, with a significant associa-
tion between the number of components of the Meta-
bolic Syndrome present and the probability of develop-
ing a cardiovascular disease.  A policy to institute rou-
tine screening in clinical practice and provision of ap-
propriate interventions for Metabolic Syndrome com-
ponents among Ghanaian adults is needed. 
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The Metabolic Syndrome (MetS), which connotes the 
clustering of known cardiovascular disease (CVD) risk 
factors including abdominal obesity, dyslipidaemia, 
hyperglycaemia and systemic hypertension, is a major 
public health challenge worldwide.
1 
The syndrome, 





, and Syndrome X
4 
was recognized at least 80 years ago.
5
 However, it was 
not until 1998 that an attempt was made by the World 
Health Organization (WHO) Diabetes Expert Group
6
 to 
provide an internationally recognized definition. Sub-
sequently, several definitions have been proposed. 
Among these, the National Cholesterol Education Pro-
gram: Adult Treatment Panel III (NCEP: ATPIII) crite-
ria
7
 which was proposed in 2001, has good clinical 
relevance and application while avoiding sophisticated 
laboratory investigations, and is therefore the most 
practical for use in our setting in Ghana.  
 
In earlier studies, using the WHO definition in the 
same population tended to give a higher prevalence 
rate of the MetS than the rate obtained with the NCEP: 
ATPIII definition.
2
 Using one criterion alone (the 
NCEP: ATPIII) in different parts of the world has 
demonstrated a variable prevalence of MetS from place 





 have been obtained for some European and 
Asian countries, while 24% of adult north Americans 
meet the diagnostic criteria for MetS.
10
 Very few popu-
lation-based studies have been conducted in Africa to 
determine the prevalence of the MetS. However, stud-





type 2 diabetes mellitus(DM) patients, using the WHO 
definition, puts the prevalence of MetS between 25.2% 
and 59.1%. The first population-based study in sub-
Saharan Africa on the MetS using multiple criteria, 
namely, the WHO, NCEP: ATPIII as well as the Inter-
national Diabetes Federation definitions, was recently 
undertaken in Cameroun.
14
 The highest prevalence 
(7.9% for men, 5.9% for women) was obtained with 
the WHO definition and the lowest (0.5% for men, 









Insulin Resistance (IR) has been identified as the pri-
mary underlying cause for the MetS and it is currently 
recognized that visceral adiposity (central obesity) is a 
major contributor to the development of both IR and 
MetS
1
 through the production of large numbers of adi-
pokines.
15
 There is also evidence to suggest a genetic 




The MetS is associated with an increased risk of devel-
oping CVD, and it serves as a simple clinical tool for 
identifying individuals with a relatively high long-term 
risk of CVD.
17 
While non-communicable diseases 
(NCD) are relatively more prevalent in developed 
countries, their impact is far more devastating in devel-
oping countries since they represent a significant bur-
den on the already under-resourced public health ser-
vice.
18
 A recent WHO report identifies CVDs as ac-
counting for 9.2% of total deaths in the African region 
in 2001
19
, and it is estimated that by the year 2015 the 
number of deaths in Africa due to NCDs in general will 
exceed that due to communicable diseases.
20
 This 
looming epidemic is adequate reason for the early insti-
tution of appropriate interventions to reduce the risk 
factors for CVD, including that related to MetS.  
 












are individual components of MetS are on the increase. 
There has also been a documented increase in CVD 
morbidity and case fatality in Ghana.
26
 Whereas these 
disorders have been reported on separately in Ghana, 
studies are yet to be done to ascertain the occurrence 
and collective impact of features of MetS on CVD 
morbidity. This study aimed at determining the fre-
quency of occurrence of MetS and its relation to car-
diovascular events at Korle Bu Teaching Hospital 
(KBTH), Accra, Ghana. 
 
METHODS 
This case-control study was undertaken at the depart-
ment of Medicine, (KBTH), Accra, Ghana, over a 12-
month period. A case was any patient who was admit-
ted to the medical ward with a stroke, acute coronary 
syndrome, peripheral arterial disease or heart failure re-
lated to hypertensive or ischaemic heart disease. Con-
trols were apparently normal age (+2 years) - and sex- 
matched individuals, 65% of whom had come to the 
hospital to undergo routine pre-employment medical 
examination. The remaining 35% were attendants at 
general internal medicine out-patient clinics at the 
KBTH. Participants (cases and controls) with chronic 
kidney disease, cancer, connective tissue disease, 
rheumatic heart disease, infective endocarditis and sep-
sis were excluded from the study after history and 
clinical examination. 
Sample size was calculated using the formula for hy-
pothesis test of odds ratio for a case –control study
30
 
(Power 80%, two-sided type 1 error 5%). Assuming an 
estimated prevalence for controls of 20% and Odds ra-
tio of 2.5, a minimum sample size of 94 was obtained 
for both cases and controls. Consecutive patients meet-
ing the inclusion criteria were recruited into the study 
after informed consent was obtained. The University of 
Ghana Medical School Research and Ethics Committee 
approved the study. 
 
Data were collected through a questionnaire, clinical 
examination and the taking of anthropometric meas-
urements. The questionnaire was administered to each 
participant(cases and controls) to obtain information on 
demographic characteristics and CVD risk factors (per-
sonal or family history of hypertension, DM or dyslipi-
daemia, tobacco use and physical activity). Physical ac-
tivity was defined as being engaged in leisure time ex-
ercise at least 3 times a week for a minimum of 
30minutes. Waist circumference was measured using a 
flexible measuring tape at the mid-point between the 
lower border of the rib cage and the iliac crest.
27
 The 
average of two blood pressure (BP) measurements 
taken 30-minutes apart on the day of examination was 
recorded. Venous blood samples were taken following 
a 12-hour overnight fast for measurement of glucose, 
total cholesterol, HDL cholesterol and triglycerides. 
Plasma glucose levels were measured using the glucose 
hexokinase method.
28
 Lipid levels were generated us-
ing ATAC 8000 random access clinical chemistry auto-
analyzer (Elan Diagnostics, USA) and LDL cholesterol 




MetS was defined using the NCEP: ATPIII criteria of 3 
or more of the following
7
: 
 Abdominal/ central obesity (waist circumfer-
ence: >102cm in men, >88cm in women) 
 Hypertriglyceridaemia>1.7mmol/L 
 (Low) HDL cholesterol (men ≤1.036mmol/L, 
women <1.295mmol/L) 
 (High) blood pressure >130/85mmHg or 
documented use of anti-hypertensive medica-
tion(s) 
 (High) fasting plasma glucose > 6.1mmol/L or 
documented use of anti-diabetic medication(s) 
 
Statistical analysis 
Analysis of the data was done with SPSS 12.0 soft-
ware. The Chi-square test and Student t-test were used 
respectively for comparison of categorical and con-
tinuous variables between the two groups. The odds ra-
tio (OR) was used to determine the association between 









Determination of the strength of association between 
MetS components and CVD was by multivariate multi-
ple logistic regressions analysis. All statistical tests 
were two-sided and the level of significance was set at 
p< 0.05.  
 
RESULTS 
One hundred cases were studied. These included 60 
(60%) stroke patients (31cases of haemorrhagic stroke, 
29 cases of infarctive stroke), 22 (22%) heart failure 
patients, 17 (17%) acute coronary syndrome patients 
and 1 (1%) patient with peripheral arterial disease. An 
equal number of age- and sex-matched controls were 
recruited. 
 
Fifty-four (54) of the cases were male and 46 were fe-
male with a male to female ratio of 1.2:1. Similarly, a 
male to female ratio of 1.2: 1 was obtained for the con-
trols. The mean age of the cases and controls were 55.6 
± 11.6 years and 54.9 ± 11.0 years respectively, with 
the difference not statistically significant. (p= 0.682). 
 
The frequency of cardiovascular risk factors for cases 
and controls is illustrated in Figure 1. Majority of both 
cases (89%) and controls (75%) were not engaged in 
any leisure-time physical activity. There was however 
a significant difference between cases and controls 
with respect to the engagement in leisure-time physical 
activity. Significant differences were also noted be-
tween cases and controls regarding the past medical 
history of hypertension, DM and CVD (p< 0.05).  
 
Fig 1: The frequency of cardiovascular disease risk 

































































The anthropometric measurements and clinical chemis-
try parameters for cases and controls are shown in Ta-
ble 1. The frequency of MetS components for cases 
and controls and the corresponding odds ratio are as 
shown in Table 2. Hypertension, the most frequently 
diagnosed component, was seen in 83% cases and 45% 
controls, followed by central obesity (54% cases and 
33% controls). MetS components were found in sig-
nificantly more cases than controls (p < 0.05).  
 
The test of association between NCEP: ATPIII indi-
vidual components and MetS resulted in central obesity 
having the highest Odds ratio of 5.38 (95% CI 3.22-
8.98), followed by hypertension and low HDL. Hyper-
triglyceridaemia (OR= 3.30, 95% CI 2.33 – 4.66) and 
hyperglycaemia (OR=3.24, 95% CI 2.22 – 4.72) had 
the lowest values (p< 0.0001) Table 2. 
 
Table 1 Comparison of anthropometric and biochemi-
cal measurements of study and control subjects. 
Variable   Cases 
Mean (SD) 


















SBP(mmHg) 160 (26) 132 (15) 0.0001 
DBP(mmHg) 99 (17) 84 (9) 0.0001 
FPG(mmol/l) 7.0 (2.5) 5.2 (0.9) 0.0001 
Total Choles-
terol (mmol/l) 
5.89 (1.79) 5.39 (1.0) 0.016 
HDL§(mmol/l) 1.20 (0.42) 1.52 (0.53) 0.0001 
TGL(mmol/l) 1.55 (0.82) 1.31 (0.71) 0.028 
LDL(mmol/l) 3.99 (1.68) 3.38 (1.09) 0.002 
 
Table 2 Frequency of metabolic syndrome components 








OR 95% CI 
Abdominal 
obesity 
54(54) 33(33) 5.38 3.22-8.98 
Hypertension 83(83) 45(45) 4.50 2.29-8.85 
Low HDL 48(48) 26(26) 3.63 2.42-5.43 
Hypertriglyc-
eridaemia 
32(32) 23(23) 3.30 2.33-4.66 
Hypergly-
caemia 
54(54) 14(14) 3.24 2.22-4.72 
HDL-High density lipoprotein cholesterol      ‡n-100 for cases and controls 
Fifty-four percent of cases and 18% of controls had 3 
or more MetS components, making the prevalence of 
the MetS among cases and controls 54% and 18%, re-
spectively. Significantly more females (cases 69%, 
controls 28.3%) than males (40.7% cases, 9.3% con-
trols) had MetS (p= 0.004).  
 
PMH Past medical history; FH Family history; *p<0.05  
 
 





The most common combination of the MetS for cases 
was hypertension, central obesity and hyperglycaemia, 
while that for controls were hypertension, central obe-
sity and hypertriglyceridaemia. The prevalence of the 
MetS was found to increase with age. Prevalence rates 
of 3.7% and 66.7% were obtained for individuals aged 
30 - 39 years and those older than 70 years, respec-
tively. However this finding was not statistically sig-
nificant.  (p= 0.227). 
 
The number of MetS components for cases and con-
trols is as shown in Table 3. For cases, 32% had 2 
components and a similar percentage was also found to 
have 3 of the MetS components. Nine percent of cases 
had all 5 components. Among the control subjects 27% 
had no MetS component, while 32% and 23% of con-
trols had either 1 or 2 components respectively. There 
was a statistically significant difference between cases 
and controls with regardto the number of MetS compo-
nents (p < 0.05).The odds ratio for the MetS was 5.35 
[95% CI 2.81-10.18, p= 0.0001]. As the number of 
components increases the odds ratio for MetS also in-
creases (Table 3). 
 
Table 3 Number of MetS components for cases and 
controls and corresponding odds ratio   
No. of MetS 
components  
Controls Cases Odds 
Ratio  
95% CI 
0 27 2 0.06 0.01-0.24 
1 32 11 0.26 0.12-0.56 
2 23 32 1.65 0.88-3.08 
3 11 32 3.81 1.79-8.10 
4 5 13 2.84 0.97-8.29 
5 2 9 4.85 1.02-23.03 
Total 100 100 - - 
 
Table 4 Association between MetS components and 
cardiovascular disease  
MetS  
Components 
 p-value**       OR ††   95% C.I. 
TGL 0.707 0.863 0.400 -1.862 
FPG 0.000 6.555 3.039 -14.139 
HDL 0.076 0.523 0.256 -1.071 
HPT 0.000 5.755 2.708 -12.230 
WC 0.109 0.565 0.281 -1.137 
Constant 0.010 0.278   
**Significance for the Wald test  
†† Predicted change in odds for a unit increase in co-
variate 
 
Multivariate multiple logistic regression analysis done 
using NCEP: ATPIII cut-off values for the MetS com-
ponents showed that hyperglycaemia (FPG 
≥6.1mmol/L) and hypertension (BP≥130/85mmHg) 
were the only MetS components with a significant as-




This is the first study on frequency of MetS among 
CVD patients in Ghana and the findings could serve as 
a backdrop for further research on the MetS in Ghana. 
High levels of known CVD risk factors such as hyper-
tension, obesity, physical inactivity and dyslipidaemia 
were seen in this study. Low proportions of both cases 
and controls were engaged in physical activity. Regular 
and sustained physical activity has been shown to im-
prove all the risk factors of MetS.
31
 Low levels of 
physical activity have been shown to be associated 
with high rates of obesity in a previous study con-
ducted in Ghana.
32
   Studies conducted in Cameroun 
found central obesity to be the key determinant of 
MetS.
14 
The finding of central obesity, which had a 
high frequency of occurrence, as the component with 
the strongest association with MetS is in keeping with 
these observations.  
 
From this study, cases had a higher number of clusters 
of MetS components than controls. This is similar to 
findings from studies on CVD patients in the Nether-
lands.
33
 The syndrome is thought to follow a progres-
sive course with the development of one risk factor, 
usually abdominal obesity, followed later over time, by 




The prevalence of MetS among cases was three times 
higher than that for controls (54% vs 18%). Prospective 
studies on MetS and the risk of CVD have shown wide 
variations in the prevalence of the MetS among CVD 
patients, however, the prevalence ranged from 23% to 
46% in majority of the studies.
35
 The prevalence of the 
MetS among the controls was comparable to rates in 
‘population-based’ studies in Asia (15%- 18%)
 8
 but 






In Africa, the prevalence rate of MetS in population-
based studies in Tunisia
36
 is comparable to that found 
among controls in this study, while lower rates have 





tively high prevalence of MetS in this study could be 
due to the high prevalence of MetS components espe-
cially hypertension and central obesity as well as the 
low levels of physical activity. In addition, all study 
subjects lived in urban areas where the prevalence rate 
of MetS has been observed to be higher than in the ru-
ral areas.
14
 In this study, MetS had a strong association 
with CVD [OR=5.35 95%CI, 2.81-10.18] and this con-











In one study, it was found that MetS was at least as 
powerful as high LDL cholesterol in predicting risk of 
CVD.
38
 Hypertension and hyperglycaemia were the 
two components of the MetS with a significantly strong 
association with the development of CVD in this study. 
However, hypertriglyceridaemia and low HDL choles-
terol were found to be strong predictors of CVD in 
studies conducted among Caucasians.
38, 39
 This brings 
to the fore the issue of racial differences with respect to 
the individual components of MetS. Indeed, it has been 
shown that hypertension carries a much greater CVD 
morbidity and mortality for people of African de-
scent.
40
 In addition; preliminary studies have shown 
that people of African descent are more insulin resis-




In view of this, researchers have proposed a framework 
for the reclassification of MetS in people of African 
descent, including the identification of different thresh-
olds for the MetS parameters.
41
 In addition, it is rec-
ommended that these parameters are weighted differ-
ently in terms of their greater risk to predict CVD in 
different racial and ethnic populations. However more 
prospective studies are needed especially in sub-





The presence of MetS is a significant predictor of CVD 
and serves as a simple clinical tool for identifying indi-
viduals with a relatively high risk of developing CVD. 
Individuals with MetS may have other metabolic risk 
factors that are not included in the standard diagnostic 
criteria. These risk factors, which impart independent 
risk for cardiovascular events, need to be identified and 
adequately treated to decrease CVD events. 
 
A nationwide assessment of the impact of the MetS on 
adult morbidity and mortality is urgently needed to-
gether with a policy to institute routine screening in 
clinical practice and provision of appropriate interven-
tions for MetS components among adults in Ghana. 
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